v3.26.1
Agreements (Tables)
 3 Months Ended
Mar. 31, 2026
Asset Acquisition [Line Items]  
Schedule Of Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values

The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):

 

License and acquired intangibles

 

$

33,569

 

Acquired research and development inventory expensed from
   asset acquisition

 

 

4,130

 

Total purchase price

 

$

37,699

 
Summary of Aggregate Amount Paid for the Assets Acquired

The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the acquisition of FYCOMPA® (in thousands):

 

Base cash payment

 

$

160,000

 

Cash paid for pro-rated prepaid expenses

 

 

1,576

 

Reimbursement on base purchase price(i)

 

 

(3,238

)

Transaction costs(ii)

 

 

5,870

 

Total purchase consideration

 

$

164,208

 

 

(i)
Recorded in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheet as of the acquisition date and reimbursement was fully applied as of June 30, 2023.
(ii)
As of September 30, 2023, the full $5.9 million was paid in cash.
Summary of Total Purchase Price Allocated to Acquired Assets

 

Inventory

 

$

4,100

 

Prepaid expenses and other current assets (samples)

 

 

130

 

Prepaid commercialization expenses

 

 

1,576

 

Property and equipment, net

 

 

433

 

License and acquired intangibles for FYCOMPA®

 

 

158,143

 

Accrued preclinical and clinical trial expenses

 

 

(174

)

Total purchase consideration

 

$

164,208

 
The straight-line method is used to amortize the license and acquired intangibles, as disclosed in Note 9 (License and Acquired Intangibles, Net).
AGAMREE [Member]  
Asset Acquisition [Line Items]  
Summary of Aggregate Amount Paid for the Assets Acquired

Initial cash payment

 

$

75,000

 

Investment in Santhera

 

 

13,465

 

Transaction costs

 

 

6,513

 

Total purchase consideration

 

$

94,978

 
Summary of Total Purchase Price Allocated to Acquired Assets

The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):

 

License and acquired intangibles for AGAMREE® (IPR&D)

 

$

81,513

 

Investment in Santhera(i)

 

 

13,465

 

Total purchase consideration

 

$

94,978

 

 

The fair value of the investment in Santhera was determined based on the closing market price (CHF 8.25) of Santhera shares and the exchange rate (1.1537) of CHF to USD on the date the shares were transferred, July 19, 2023.